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1. Introduction 
Increased efforts have been made during the last few decades to develop new technologies 
capable of identifying and quantifying the expression proteome in different cellular systems 
in physiological and physiopathological conditions for determining illness biomarkers, 
pharmaceutical targets and/or posttranslational modifications (PTM) by means of 
proteomic techniques. 2D gel electrophoresis, with immobilized pH gradients, associated 
with mass spectrometry, is one of the fundamentals steps in studying proteomics. The 2D 
technique can be used in studying the quantitative expression of protein profiles according 
to iso-electric point (Ip), molecular weight (Mr), protein solubility and the relative 
abundance of the above. This methodology provides a protein profile reflecting changes in 
protein expression levels, isoforms and PTM. 
Proteins can be classified into those known by their structure and function, those recognized 
by determined domains and about which there is some knowledge, and those whose 
function is still not known. Proteomics is defined as the large-scale study of proteins 
expressed for a specific tissue from a genome, (global proteomics) or differentially expressed 
proteins (differential proteomics). Determining differentially expressed proteins, or proteins 
suffering a change in physiological circumstances, is the clue to understanding such 
pathology’s cellular mechanisms. Although an expressed gene in specific tissues (as an 
answer to biologic alterations) could be analyzed by a mRNA expression study 
(transcriptomics), these results do not always coincide with the expected expression profiles 
since the number and activity of proteins associated with the same regulation in different 
stages could be modified. Genomic data integration is required, as well as transcritomics, 
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proteomics, variome, peptidomics, and metabolome to understand physiological 
phenomenon in a comprehensive manner. 
Systemic sclerosis (SSc) is a chronic illness of the connective tissue having unknown 
etiology; it has a variable course and severity and is characterized by intercellular matrix 
alterations and secondary fibrosis of enormous amounts of connective tissue. This results 
in hardening and thickening of the skin, alterations in the microvasculature and the large 
vessels, secondary to changes in the endothelial cells together with Raynaud’s 
phenomenon, self-immunity alterations, and musculoskeletal and visceral degenerative 
fibrotic changes (1). 
Despite recent advances having been made in understanding some molecular pathways 
involved in SSc, its etiopathogenesis remains unknown. Treatment for these patients has 
had very limited effectiveness, and the natural course of the illness inevitably leads to a fatal 
outcome. A better understanding of the illness’ physiopathology is required to be able to 
orientate suitable therapeutic measures, carry out effective monitoring of its response, and 
determine severity criteria indicating a bad prognosis for the illness. This is where 
genomics, micro-array analysis and proteomics appear as valuable therapeutic and 
diagnosis tools. 
Several groups have reported gene expression profiles for SSc-patient’s tissues and cells 
(2-6). 
Zhou found that fibroblasts in SSc patients showed different RNAm expression profiles 
for fibrilarine autoantigens, B centromere protein, P27 centromeric autoantigen , RNA 
polymerase I , DNA topoisomerase I, and PMScl (2). Luzina found high chemokine and 
cytokine levels in bronchoalveolar lavage (LAB) in SSc patients (3). Whitfield examined 
skin biopsies in four SSc patients, identifying 2,776 genes which expressed themselves in 
different ways to that of healthy controls (4).Tan (using a fibroblast culture) identified 62 
genes which expressed themselves in different ways in SSc (5). Zhou reported fibroblast 
micro-array analysis results for fibroblasts from 18 sets of discordant twins in SSc (6,7). 
Protein analysis using two-dimensional electrophoresis electrophoresis on polyacrylamide 
gel (2D PAG) will contribute to and extend the knowledge produced by analyzing gene 
expression, especially for proteins undergoing crucial PTM in their function. 
Proteomic analysis involves many methodologies orientated towards identifying and 
characterizing altered proteins as a result of illness. Thousands of proteins are evaluated in 
just one trial in such studies, leading to detecting expression profiles as a consequence of 
abnormality in cell function or interaction. Traditional methods used in proteome analysis 
have included 2D PAG where proteins are first separated according to their electric charge 
and then by their mass in the second direction before being stained, thus allowing mixtures 
of 1,000 to 3,000 proteins to be visualized. The development of special software and the use 
of Internet have allowed multiple genes and databases to be compared. When being 
combined with mass spectrometry, a separation appears which allows efficient 
identification of proteins of interest, including many of their PTM. This analysis can be 
applied in comparative studies of expression profiles during different stages of the illness or 
healthy tissue compared to affected tissue, thus being able to identify the different 
modifications in the protein characteristics of clinical interest in different illnesses (8). 
Clinical proteomics is aimed at identifying proteins involved in pathological processes, as 
well as evaluating changes in their expression during different stages of an illness. 
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Proteomics in clinical practice offers the technical skill for identifying biomarkers for 
diagnosis and therapeutic intervention. Potential biomarkers developed from proteomic 
analysis will have further specificity and sensitivity in clinical trials, since they measure 
protein alteration involved in an illness (9). A good understanding of data management, 
correlation, interpretation, and validation is crucial in obtaining precise results contributing 
towards understanding cellular alterations which could be involved in developing SSc. 
Only two proteomic studies were found in the current literature. Rottoli has analyzed the 
type of immune response and protein composition in pulmonary fibrosis patients’ LBA 
medium associated with SSc, sarcoidosis and idiopathic pulmonary fibrosis. Proteomic 
analysis revealed quantitative differences between the three illnesses, finding increased 
SSc in plasmatic proteins such as alpha1-beta glycoprotein, C3 complement, alpha 1- 
antitrypsin, beta- haptoglobin, and prothrombin (10,11). Czubaty has used a commercial 
cell line (HeLa S3) for proteomic analysis of Topoisomerase I protein patterns by 
comparing co-immunoprecipitation with mass spectrometry and identified 36 new 
proteins which were associated with Topoisomerase I and their possible interaction site in 
the RRM domain (12). However, these studies have been carried out in a not very specific 
medium, such as LBA. 
A two-phase fibroblast proteomic study was thus proposed (pre-treatment and post-
treatment) in fibroblasts, these being the cells initially involved in SSc physiopathology in 
one of its most important expressions: fibrosis. Fibrosis is one of the pathognomonic 
pathological findings for SSc, representing one of the most exemplary phenotypes. 
Characteristically, there is uncontrollable collagen production and that of other extracellular 
matrix proteins due to resident fibroblasts in the skin, lungs and other vital organs leading 
to an excessive accumulation of connective tissue. As the illness progresses, this increased 
deposit of connective tissue alters the tissues’ normal architecture, ending in a functional 
alteration of the latter and determining a very significant involvement in morbidity-
mortality of patients suffering fibrosis-related SSc (13). 
Protein expression pattern was observed when carrying out a proteomic analysis on SSc 
patients’ fibroblasts during different stages of the illness and comparing them to healthy 
individuals’ fibroblasts. Their appearance was analyzed and thus an increase, decrease, or 
absence of their profiles was determined, looking for an association of the proteins found 
with phases and serological and clinical characteristics. Proteins involved in the illness’ 
etiopathology during its different stages were isolated as this could have therapeutic 
implications in an illness in which current treatment is very limited and not very efficient. 
2. Materials and methods 
2.1 Patients 
This was a cases and controls study in which 11 patients who fulfilled with American 
College of Rheumatology SSc criteria were included during different phases of the illness 
(14,15) and subdivided into two groups: limited SSc and diffuse SSc, according to the 
parameters proposed by Le Roy (1). Table 1. 
The cutaneous involvement of the skin was evaluated according to the modified Rodnan 
index (16) which ranges from 0 (normal) to 3 (severe), measured in 17 different body areas 
(maximum possible score is 51). 
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Clinical features SSc Patients (n=11) 
Age at onset/yrs 44.75 ±10 
Female/male ratio 3:01 
Disease duration yrs 9,65 ± 4 
SSc subtype 
lSSc 7 
dSSc 3 
Morphea 1 
Raynaud phenomenon % 90 
Raynaud duration, yrs 9.1 ± 4 
Rodnan Score 22.1 ± 9 
Calcinosis % 45 
Telangiectsias % 64 
Renal Crisis % 0 
Digital ulcers % 0 
Gastrointestinal involvement % 20 
Pulmonary involvement % 0 
Antibodies Anticentromere % 60 
Antibodies Anti SL-70 % 30 
Antibodies Antinuclear % 90 
Table 1. General characteristics of SSc patients 
Patients had no treatment or had suspended 4 weeks before taking the biopsy (a treatment 
scheme was defined as involving any of the following medications, alone or combined: 
prednisone, D-penicillamine, colchicine, micophenolate mofetil, methotrexate, 
cyclophosphamide). 
Healthy controls were individuals without an autoimmune illness or who had not 
undergone previous immunodepressor treatment. 
Registration forms were completed; they then contained SSc patients’ demographic data, 
clinical characteristics and antibody levels. 
All individuals involved in the study signed the participation consent form according to 
established ethical norms. 
2.2 Skin biopsy 
Following the cutaneous biopsy technique’s guidelines by means of punch (17), two skin 
biopsies were taken from each SSc patient: a skin sample with SSc involvement obtained 
from the body area having the maximum Rodan score and another clinically healthy skin 
sample having a zero Rodan score. The same technique was used for a skin biopsy of 
healthy individuals taken from a non-esthetic non-visible area. The material was prepared 
for cell culture. 
2.3 Obtaining fibroblasts from skin biopsies from healthy controls and SSc patients  
This stage of the study, as well as the rest of the procedures, had been previously agreed on 
by the interdisciplinary team for which the critical route in each process was determined. 
Clear coordination of activities was needed to guarantee that: 
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 The patients were appropriately and conveniently informed about the investigation and 
the lab procedures that would be carried out for analyzing samples; 
 The biopsies would arrive at the lab immediately after samples had been taken to 
ensure rapid processing; and 
 Serum taken from patients was convenient and suitable for lab procedures. 
 According to previously-defined protocols, the sample should have arrived at the lab 
on the day the sample was taken as follows (18): 
 Tubes marked with the names of the patients, indicating whether the fragment of skin 
had been taken from a clinically healthy area or from a clinically sick one; and 
 Dry tubes to take the blood sample from the same patient. 
The following procedures had been previously carried out in the lab: 
 Preparation of the means of transport for the biopsy: A DMEM medium was used with 
a F-12 medium supplemented with an antibiotic solution (100ug/ml streptomycin, 
0.25ug/ml B anphotericin) at 3% in sealed sterile glasses; and 
 Preparation of the material and supplies for the culture: a culture medium was 
prepared to be supplemented with autologous human serum. 
The skin biopsies immersed in the transport medium and the serums were transported at 
4°C and taken to a lab specializing in human fibroblast cultures. Once in the lab, the samples 
were processed in the white zone, cell culture room, in the safety cabin following 
management protocols for these areas, according to the Lab Quality Manual. 
 Each sample was washed three times with HANK´s saline solution supplemented at 3% 
with antibiotic and antimycotic solution (100mg/ml penicillin, 100ug/ml streptomycin, 
0.25ug/ml B anphotericine); 
 The samples were cut by a scalpel into small explants (half millimeter maximum size). 
The fragments so obtained were planted as explants in six-well culture plates; 
 A total blood sample was taken from each patient in a dry tube to obtain serum by 
centrifuging at 2,500 rpm for 20 minutes at room temperature, with which the fibroblast 
culture medium would be autologously supplemented;  
 2ml DNEM culture medium with F-12 supplemented at 20% with autologous serum 
and 1% antimycotic antibiotic solution was added to each well; and 
 Each sample was identified with a number for each patient, followed by whether the 
sample was healthy or unhealthy. 
The cultures were monitored daily under an inverted microscope at 10X by 40X enlargement: 
 Observations and photographs were registered; 
 The culture medium was changed every third day; and 
 The first cells began to be observed during the second week after culture. 
Confluence was obtained around the fourth week. 
Cell preparation for obtaining the proteins was carried out, following the following steps: 
 Cells were previously washed with 1X PBS solution; 
 Once the washing solution had been removed, 600 ul extraction protein buffer was 
added to each well as described in the protocol for 2D electrophoresis or Trizol study 
for obtaining NRA; and 
 The fibroblasts were incubated for 10 minutes and then homogenized with the help of a 
rake. Cell separation was confirmed with an inverted microscope and each well’s content 
was placed in a 1.5 ml Eppendorf tube and stored at -80°C until proteins were analyzed. 
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3. 2D electrophoresis for analyzing human fibroblast proteins in SSc patients 
and controls 
14 fibroblast culture samples were studied by 2D-SD PAGE obtained from skin biopsies 
from three healthy controls and skin from a healthy and unhealthy region in 11 SSc patients. 
A recognition code was assigned. All individuals involved in the study signed the 
participation consent form, according to the ethical standards for such protocol. 
The fibroblasts were lysed in a 600 ul protein extraction buffer made up of 7M thiourea, 2M 
ABS-14 detergent (1%), 40 mM Tris base and 0.001% bromophenol, all of which form part of 
BIO RAD protein extraction kit (cat. 163-2086). Anpholites (pH 3-10) were added at 200 mM 
final concentration before starting the lysis for reducing cysteine disulphide links. 
The samples suspended in lysis buffer were initially sonified on ice to break up the genomic 
DNA cells and fragments (10%). The product was spun at 16,000 g for 20 minutes, 
separating proteins from the remains of cells and other macromolecules. These samples 
were stored at -80°C until subsequent analysis. 
The Lowry method (RC DC, assay protein, Bio-Rad) was used for protein quantification; 
uni-dimensional electrophoresis was carried out by means of Laemmli’s method to obtain 
an electrophoretic map and thus guarantee the integrity of proteins from fibroblast lysates. 
Once protein concentration and integrity had been verified, 2D PAG SDS electrophoresis 
trials were carried out. Electrophoresis was carried out on 10% and 12% acrylamide gels 
(30%/0.8v/v acrylamide/bisacrylamide), best results being obtained at 12%. 
Isoelectrofocusing (IEF) followed BIO RAD’s recommended method (cat.163-2105); 7 cm IPG 
strips, pH 3-10 and pH 4-7 ranks were selected. The latter were placed on trays to hold 
samples of interest suspended in rehydration buffer (125ul total volume); this buffer 
contained (m urea, 2% CHAPS, 50 Mm dithiethreitol (DTT), 3-10 anpholites (0.2%) and blue 
bromophenol traces. The fibroblast lysates were left (for one or two hours) and it was 
verified that the gel was totally covered by the previous solution, after which mineral oil 
was placed on the strip to avoid evaporation. The samples were covered and incubated for 
sixteen hours. Two functions were fulfilled in this step: the strips were hydrated and the 
samples were absorbed by the pH strip gel (which is why time taken and conditions for this 
procedure were so important). 
Human fibroblast culture protein IEF was carried out on Protean IEF Cell equipment (BIO 
RAD), initially on a linear gradient until reaching 250V for 30 minutes, then at 4,000V for 2 
hours on a linear gradient and finally on a fast ramp until the equipment reached 12,000V 
when the IEF finished. Small wicks of filter paper were placed before passing the strip from 
the hydration tray to the IEF equipment; they were moistened with ultrapure water and the 
strip was then placed. However, everything had to be covered with mineral oil so as to 
avoid evaporation before starting the process. 
The 2D in which the proteins were separated according to weight was developed on 12% 
gels according to the preliminary analysis. Once the IEF was finished, the strips were 
separated from the electrode and placed in the equilibrium solution trays again, with 2% of 
equilibrium buffer I (6M urea, 2% SDS, 0.375M Tris-HCl (pH 8.8), 20% glycerol and 2% 
DTT). They were incubated for 10 minutes, the disulphur groups thus being reduced. The 
strips were then incubated for 10 minutes in equilibrium II buffer (6M urea, 2% SDS, 0.375M 
Tris-HCl (pH 8.8), 20% glycerol and 0.5g iodoacetamide). The sulphidryl groups were 
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removed to avoid reduction reversibility. This step was repeated, but this time the strips 
were placed in the 2D running buffer (tri/glycine/SDS at pH 8.8). 
Meanwhile the 2D gel was placed in low fusion point agarose solution which was dissolved 
in SDS_PAGE running buffer. The proteins were separated in BIO RAD chambers, whether 
with Mini-Protean 3 cell (cat165-3301/02) or Mini-Protean Tetra cell (CAT 165-8000/01); the 
procedure began with a 40V voltage and was slowly increased to 60V voltage. 
Once the proteins had been separated in 2D, they were silver stained according to 
manufacturer’s recommendations (Invitrogen, Silver Express staining kit, cat.LC 61000). 
The gels were documented with Quantity One 1-D Analysis Software and differential 
expression points were found with PDQuest 2-D Analysis Software. 
The spots or differential expression points between controls and patients were analyzed 
with MALDI-TOF/TOF (4700 Proteomics Analyzer, Applied Biosystems). Four points were 
split and sent to the Córdoba University’s central research support service (SCAI) 
proteomics unit in Spain. 
It should be pointed out that the best results obtained in separating proteins from fibroblasts 
in patients and controls by means of 2D electrophoresis were on 4-7 pH strips and 12% gels. 
All 2D electrophoresis trials were carried out from the same human fibroblast culture lysate 
for both patients’ samples and triplicate controls. 
4. Statistical study 
The results were presented descriptively with measurements, medians and interquartile 
ranges expressed according to expected variables. Association measurements having 
binominal categorical variables were presented in the analysis, depending on population 
distribution. A Wilcoxon or Mann-Whitney chi square test was used and association was 
measured by odds ratio (OR). Controls having similar conditions to the chosen patient cases 
regarding age and gender were sought to avoid differential expression which could have 
been explained by a physiological condition associated with these two variables and which 
could have increased or decreased potential associations. 
5. Results 
Proteins in cells from silver stained fibroblast cultures were observed in representative 2D 
SD-Page electrophoresis. The trials were carried out on 12% gel and IPG strips having pH4-
7. Standardization studies were carried out on strips having pH 3-10 but most proteins were 
located in the pH 4-7 range where better resolution appeared. Each fibroblast sample was 
analyzed by 2D electrophoresis in triplicate. 
2D electrophoresis images of human fibroblast proteins from controls and SSc patients 
were analyzed by PDQest software allowing the gels to be normalized. Proteins (spots) 
which were differentially expressed in controls and scleroderma patients (marked with 
arrows and numbers on each gel in Figure 1) were isolated, digested with trypsin and the 
peptides so produced were analyzed by mass spectrometry (peptide mass fingerprints) 
(MALDI-TOF). The analyzed spots from silver stained gels as well as isolated ones stained 
with Coomasie blue were mainly from different haptoglobin protein isoforms (Table 2), 
having greater than  
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Table 2. Proteins identified by mass spectrometry (MALDI/TOF- TOF) which were 
separated by 2 D electrophoresis and obtained from cultures of human fibroblasts from SSc 
patients and healthy subjects. The proteins corresponding to isolated spots in Figure 1, 
which differ in expression profile between controls subjects and patients. 
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99% protein score confidence interval (the search will be more credible the nearer this is to 
100 but confirmation must be above 99%). The protein score is a score given by a search 
engine (MASCOT) to each identified peptide, according to the probabilistic system based on 
peptide mass distribution, depending on the mass of the protein to which they belong 
(Mowse System). These were identified by comparing the MALDI-TOF peptide map to the 
theoretic value calculated for peptides from all SWISS-PROT database proteins and the 
TrEMBLE database for human sequences and by applying Mascot software. Proteins 
corresponding to spots identified by MALDI-TOF (Table 2) were correlated with their 
molecular weights and isoelectric points when located on the 2D gels (Figure 1 and 2)  
 
 
Fig. 1. Representative electrophoresis of proteins obtained from isolated lysates human 
fibroblasts cultures from skin biopsies of healthy and Scleroderma patients using 2D SDS - 
PAGE (12% ). Healthy controls (A, D) SSc patient F11, healthy skin (B) and diseased skin (C) 
SSc patient F7, healthy skin (E) and sick skin (F). IPGs strips were used (pH 4- ) and staining 
of the gels were developed with silver reagent. 
 
                      A         B     C
 
Fig. 2. Amplified region noted in Figure 1. 2D electrophoresis of human fibroblast proteins 
corresponding to differentially expressed spots were identified by MALDI-TOF/TOF (4700 
Proteomics Analyzer, Applied Biosystems). Healthy controls (A, D) SSc patient F11, healthy 
region (B) and diseased region (C) SSc patient F7, healthy region (E) and sick region (F). 
www.intechopen.com
  
T
ab
le 3. M
ain
 clin
ical an
d
 sero
lo
g
ical v
ariab
les an
d
 in
ten
sity
 o
f ex
p
ressio
n
 o
f th
e sp
o
ts in
 
C
o
lo
m
b
ian
 p
atien
ts su
fferin
g
 S
S
c 
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Patient at onset, yrs Duration, yrs Duration, yrs Antinuclears Score
1 29 7 Absent 0 Negative Negativo 0 0 Absent Absent Absent Absent Absent Absent
2 42 3 Present 6 Positive Centromere 40 16 Present Absent Present Present Present Present
3 27 1 Present 8 Positive Centromere 1260 26 Present Absent Present Present Present Present
4 48 7 Present 10 Positive Centromere 1260 18 Present Present Present Present Present Present
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10 20 20 Present 20 Positive Centromere 1240 23 Present Present Present Present Present Present
11 48 14 Present 15 Positive Centromere 160 23 Present Present Present Absent Absent Present
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presenting approximately identical molecular weight but having a different isoelectric point, 
thus reflecting different protein processing mechanisms as previously described in 
scleroderma patients. Table 2 shows the identity of haptoglobin isoforms in scleroderma-
derived human fibroblasts in scleroderma patients. 
It was determined whether there were any associations between the clinical and serologic 
variables and the intensity of the spots’ expression. Gender, initiation age, Raynaud’s 
disease duration, pulmonary hypertension, antinuclear antibodies’ pattern and dilution, 
modified Rodnan index, microstomy, calcinoses, telangiectasia and classification of the 
illness were then categorically and quantitatively evaluated with dominant spots’ 
expression intensity, without finding any type of association (Table 3 and 4). 
 
Characteristic Health Skin Sick Skin
Microstomy 0,72 0,821
Antibodies antinuclear 0,465 0,602
Calcinosis 0,97 0,821
Sclerodactilia 0,43 0,502
Hyperpigmentation 0,152 0,821
Hypopigmentation 0,233 0,821
Telangiectasia 0,437 0,502
SSc Subtype 0,151 0,119
PAH 0,181 0,978  
Table 4. Association between clinical characteristics and expression of the spots. Measured 
by the intensity of protein electrophoresis. Determined by Chi square - p value 
6. Discussion 
Despite recent advances in understanding some molecular paths involved in SSc, its 
etiopathogenesis still remains unknown. Treating these patients has very limited 
effectiveness and the disease’s natural course inevitably leads to a fatal outcome. A better 
understanding of its physiopathology is required to orientate suitable therapeutic treatment 
for efficiently monitoring its response and determining severity criteria indicating a poor 
prognosis for the illness. Genomics, micro-array analysis and proteomics thus appear as 
valuable diagnostic and therapeutic tools. 
Proteomic analysis uses many methodologies orientated towards identifying and 
characterizing altered proteins as a result of illness. Millions of proteins are evaluated in one 
trial in these studies, leading to the detection of expression profiles as a consequence of 
abnormal function or cell interaction. The traditionally-used methods in proteomic analysis 
include 2D electrophoresis on polyacrylamide gel where proteins are separated first 
depending on their electric charge and then by their mass in the second direction and finally 
stained, visualizing 1,000 to 3,000 proteins. Special software having been developed and the 
use of internet have led to many genes and databases being compared. Separation is 
achieved when combined with mass spectrometry leading to the efficient identification of 
proteins of interest, including many of their PTMs. Such analysis can be applied to 
comparative expression profile studies during different stages of the illness or comparing 
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healthy tissues to unhealthy tissues, thereby identifying modifications in the characteristics 
of t proteins of clinical interest in different illnesses. 
Haptoglobin was identified in the current study after proteomic analysis in fibroblasts from 
SSc patients during different stages of the illness as being a protein which expressed itself in 
a different but constant way in all SSc patients by contrast with healthy individuals. 
Haptoglobin is an acute phase protein, indicative of different pathological conditions such 
as forms of cancer, hepatic cirrhosis and hepatitis C. This protein appears with around 6 
phenotypes, besides combinations in PTM, such as glycolization and deamination, thus 
increasing the number of presentation forms (19). 
Recent studies have demonstrated that idiopathic pulmonary fibrosis is caused by alteration 
of protein expression involved in different processes such as matrix remodeling, 
inflammation and tissue damage and repair. Similar studies to the current study (carried out 
in LBA in pulmonary fibrosis by proteomics) have demonstrated that this protein’s 
expression significantly increased (20). However, the advantage of this study was the 
identification of this protein in a fibroblast culture, cells directly involved in the illness’s 
physiopathology and whose increase did not correlate to the illness’ severity but to its 
presence, thereby assuming that high haptoglobin values can predict SSc development. 
Once haptoglobin has been identified as a protein present in untreated SSc patients, 
proteomic studies must be carried out to analyze this protein’s behavior when influenced by 
different therapeutic schemes. Such study is currently taking place. 
7. Conclusion 
Identifying haptoglobin in a fibroblast culture in untreated SSc patients did not correlate 
with the severity of the illness but with its presence. It could thus become a predictive tool 
for SSc development. However, it is worth studying its behavior in the same patients using 
different therapeutic schemes and prospective studies are needed including a bigger 
population to verify these observations. 
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